The patent protection for Novo Nordisk's blockbuster semaglutide is weakening. As exclusivity begins to expire, a wave of generic versions is poised to enter the market. This shift threatens the high-cost model for weight-loss drugs, potentially triggering a fierce pricing battle in major international markets where branded treatments remain prohibitively expensive for many.

This impending competition represents a major turning point for global healthcare. For years, patients in countries like China, India, Brazil, and Canada have faced steep prices for drugs like Ozempic. Cheaper generics could unlock access for millions struggling with obesity and diabetes, fundamentally altering treatment dynamics and challenging the revenue streams that have fueled the pharmaceutical industry's recent boom.

All eyes now turn to Novo Nordisk and its response. The company will likely deploy legal defenses and new formulations to delay generic entry. Meanwhile, rival Eli Lilly watches closely as its own drug faces similar patent cliffs. The coming years will determine if this price war delivers on its promise of affordable care or if brand loyalty and regulatory hurdles blunt the impact.